SCHEMBL20227686

SCHEMBL20227686

O=c1c2ccccc2c2ccccc2n1-c1ccc(-c2ccc3c(-c4ccccc4)c4ccccc4c(-c4ccccc4)c3c2)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.55
MAPK1 P28482 1/20 0.46
L3MBTL1 Q9Y468 2/20 0.42
NPSR1 Q6W5P4 1/20 0.42
KDM4E B2RXH2 5/20 0.41
ATM Q13315 1/20 0.41
MEN1 O00255 2/20 0.40
LMNA P02545 2/20 0.40
ALDH1A1 P00352 2/20 0.40
POLB P06746 1/20 0.40
TSHR P16473 1/20 0.40
BRCA1 P38398 1/20 0.40
HSD17B10 Q99714 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
MAPT P10636 3/20 0.39
HSP90AA1 P07900 1/20 0.39
RCE1 Q9Y256 1/20 0.39
BRD4 O60885 1/20 0.39
CYP1A2 P05177 1/20 0.39
GLA P06280 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20227688 0.95 KMT2A (0.51) KMT2AMAPK1L3MBTL1NPSR1KDM4E
SCHEMBL20227518 0.93 KMT2A (0.61) KMT2AMAPK1L3MBTL1NPSR1KDM4E
SCHEMBL20227682 0.92 KMT2A (0.56) KMT2AMAPK1L3MBTL1NPSR1KDM4E
SCHEMBL20227561 0.92 KMT2A (0.55) KMT2AMAPK1L3MBTL1NPSR1KDM4E
SCHEMBL20227749 0.92 KMT2A (0.55) KMT2AMAPK1L3MBTL1NPSR1KDM4E
SCHEMBL20227701 0.91 KMT2A (0.52) KMT2AMAPK1L3MBTL1NPSR1KDM4E
SCHEMBL20227566 0.91 KMT2A (0.49) KMT2AMAPK1L3MBTL1NPSR1KDM4E
SCHEMBL20227693 0.91 KMT2A (0.53) KMT2AMAPK1L3MBTL1NPSR1KDM4E
SCHEMBL20227747 0.90 KMT2A (0.59) KMT2AMAPK1L3MBTL1KDM4EATM
SCHEMBL20227687 0.90 KMT2A (0.56) KMT2AMAPK1L3MBTL1NPSR1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11713319-B2 Compounds having valerolactam structures MERCK PATENT GMBH (DE) 2023-08-01 US disclosed
US-11713319-B2 Compounds having valerolactam structures MERCK PATENT GMBH (DE) 2023-08-01 US disclosed
EP-3548467-B1 COMPOUNDS HAVING VALEROLACTAM STRUCTURES MERCK PATENT GMBH (DE) 2023-06-21 EP disclosed
US-20200031827-A1 COMPOUNDS HAVING VALEROLACTAM STRUCTURES MERCK PATENT GMBH (DE) 2020-01-30 US disclosed
WO-2018099846-A1 COMPOUNDS HAVING VALEROLACTAM STRUCTURES MERCK PATENT GMBH (DE) 2018-06-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11713319-B2 Compounds having valerolactam structures ACE, CYP3A4, CYP2D6 KMT2A 1161/4885MAPK1 2970/4885L3MBTL1 4233/4885
US-20200031827-A1 COMPOUNDS HAVING VALEROLACTAM STRUCTURES ACE, CYP3A4, CYP2D6 KMT2A 1161/4885MAPK1 2970/4885L3MBTL1 4233/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.